RxDoctor Payments Data

Else Jensen, MD

Internal Medicine · Berkeley, CANPI 1790754885

Payments from drug & device makers

$769in general payments, 2019–2025

Across 13 payments — averaging $59.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$332
  • Amgen$182
  • Novo Nordisk$151
  • Inspire Medical Systems, Inc.$39
  • Exact Sciences$23
  • Dexcom, Inc.$22
  • plus $21 from 1 others

What the payments were for

  • Food & beverage$769100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$769 in reported general payments places this provider in the 70th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$102,829
Medicare patients
290
Services billed
965

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide27$29,022
EliquisApixaban15$15,351
Breo ElliptaFluticasone/Vilanterol21$12,004
SynthroidLevothyroxine Sodium29$2,486
Celecoxib42$2,334
Atorvastatin Calcium185$2,180
Levothyroxine Sodium168$1,993
Rosuvastatin Calcium126$1,531
Duloxetine Hcl35$1,406
Losartan Potassium181$1,384
Metoprolol Succinate75$1,233
Pantoprazole Sodium66$1,062
Omeprazole82$1,049
Ezetimibe26$953
Albuterol Sulfate HfaAlbuterol Sulfate23$904

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$151$29,02227 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Berkeley

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →